Managing Trial Data When Patients Switch Treatment Groups
Although allowing patients in the control group of a clinical trial to switch onto the experimental treatment is a common occurrence in oncology drug trials, it can present significant challenges for the accurate interpretation of trial findings when a substantial number of patients switch treatments. A GPC team is now exploring how to manage treatment switching in the design and analysis of oncology drug trials, to help ensure that the trial results are meaningful and appropriately construed.